Immutep Limited

IMM

AU000000IMM6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:40:53 31/05/2024 am IST			5-day change	1st Jan Change
0.45 ^AUD	+2.27%		+1.12%	+30.43%

17/05	Capital One Initiates Immutep at Overweight Rating With $10 Price Target	MT
15/05	Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	MT

Immutep Limited Announces Cessation of Mr. Albert Wong as Director

November 22, 2017 at 12:36 pm IST

Immutep Limited announced that Mr. Albert Wong has ceased to be director of the company from September 21, 2017.

Latest news about Immutep Limited

Capital One Initiates Immutep at Overweight Rating With $10 Price Target	17/05	MT
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	15/05	MT
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	15/05	CI
Immutep Limited Announces Initial Clinical Data from EFTISARC-NEO	03/05	CI
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05	CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	02/05	MT
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024	30/04	CI
Canaccord Starts Immutep at Buy, Price Target is AU$1.00	30/04	MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	25/04	CI
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	25/04	MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	24/04	CI
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	18/04	CI
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	18/04	MT
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17/04	CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	17/04	MT
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial	17/04	MT
Encouraging results for Immutep's cancer therapies	25/03	FI
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti	05/03	CI
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss	28/02	MT
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02	CI
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer	04/01	CI
Immutep Doses First Patient in Cancer Trial	04/01	MT
Immutep Limited Announces Change of Registered Office Address	22/12	CI
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	21/12	CI
Immutep Receives $1.7 Million Research, Development Tax Incentive From French Government	07/12	MT

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Immutep Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.45 AUD

Average target price

0.978 AUD

Spread / Average Target

+117.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUTEP LIMITED	+30.43%	36Cr
MODERNA, INC.	+43.36%	5.46TCr
IQVIA HOLDINGS INC.	-5.31%	3.99TCr
LONZA GROUP AG	+37.52%	3.88TCr
ICON PUBLIC LIMITED COMPANY	+14.75%	2.69TCr
CELLTRION, INC.	-12.56%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	1.88TCr
BIO-TECHNE CORPORATION	+0.04%	1.22TCr
UNITED THERAPEUTICS CORPORATION	+25.12%	1.22TCr
MEDPACE HOLDINGS, INC.	+26.04%	1.19TCr

Other Biotechnology & Medical Research

Immutep Limited

Equities

IMM

AU000000IMM6

Biotechnology & Medical Research

Immutep Limited Announces Cessation of Mr. Albert Wong as Director

Latest news about Immutep Limited

Chart Immutep Limited

Company Profile

Income Statement Evolution

Ratings for Immutep Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research